{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:28:33Z","timestamp":1792182513727,"version":"4.4.0"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007923","name":"Yangtze University","doi-asserted-by":"publisher","award":["2022MIF07"],"award-info":[{"award-number":["2022MIF07"]}],"id":[{"id":"10.13039\/501100007923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cholangiocarcinoma (CCA) is a clinically and molecularly heterogeneous malignancy originating from the biliary epithelium. It represents the second most common primary liver cancer after hepatocellular carcinoma (HCC). Despite advances in understanding CCA pathobiology and improving diagnostic modalities, its global incidence and mortality continue to rise. Most patients are diagnosed at advanced stages, which are characterized by frequent recurrence, metastasis, and therapeutic resistance, leading to poor clinical outcomes. The mammalian target of rapamycin (mTOR) signaling pathway is a central regulator of cell growth, metabolic reprogramming, survival, and autophagy; its dysregulation significantly contributes to CCA initiation and progression. However, the precise roles of mTOR signaling across different CCA subtypes remain incompletely understood, and conflicting evidence exists regarding its context-dependent functions in tumor progression and therapeutic response. This review provides a comprehensive overview of recent advances in mTOR research in CCA, focusing on its involvement in metabolic reprogramming, malignant phenotypes, autophagy, apoptosis, and treatment resistance. Furthermore, current limitations and knowledge gaps in targeting mTOR signaling are discussed, alongside emerging therapeutic strategies, such as mTOR inhibitors, combination approaches, and natural small-molecule modulators. Finally, future research directions and the potential of mTOR-centered interventions to improve clinical outcomes in CCA are highlighted.<\/jats:p>","DOI":"10.3389\/fphar.2026.1882709","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:39:16Z","timestamp":1784090356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenxuan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Yangtze University, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Yangtze University, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jpp\/rgab036","article-title":"Atractylodin inhibited migration and induced autophagy in cholangiocarcinoma cells via PI3K\/AKT\/mTOR and p38MAPK signaling pathways","volume":"73","author":"Acharya","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12122","DOI":"10.1038\/srep12122","article-title":"Results of an abbreviated phase II study with the AKT inhibitor MK-2206 in patients with advanced biliary cancer","volume":"5","author":"Ahn","year":"2015","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms25010461","article-title":"Molecular profile of intrahepatic cholangiocarcinoma","volume":"25","author":"Andraus","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"105364","DOI":"10.1016\/j.phrs.2020.105364","article-title":"Prospective therapeutic potential of tanshinone IIA: an updated overview","volume":"164","author":"Ansari","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1083\/jcb.201306041","article-title":"Where is mTOR and what is it doing there?","volume":"203","author":"Betz","year":"2013","journal-title":"J. Cell Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.3748\/wjg.v23.i23.4311","article-title":"Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation","volume":"23","author":"Bian","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Balasundaram","year":"2017","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cub.2008.07.078","article-title":"Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-Mediated raptor phosphorylation","volume":"18","author":"Carri\u00e8re","year":"2008","journal-title":"Curr. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"22830","DOI":"10.3390\/ijms160922830","article-title":"Targeting glutamine induces apoptosis: a cancer therapy approach","volume":"16","author":"Chen","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.18632\/oncotarget.1706","article-title":"Antitumor activity of the combination of an HSP90 inhibitor and a PI3K\/mTOR dual inhibitor against cholangiocarcinoma","volume":"5","author":"Chen","year":"2014","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"156022","DOI":"10.1016\/j.phymed.2024.156022","article-title":"Hypocrellin A suppresses intrahepatic cholangiocarcinoma via multi-target inhibition of the PI3K\/AKT\/mTOR, MAPK, and STAT3 signaling pathways","volume":"135","author":"Chen","year":"2024","journal-title":"Phytomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1078-0432.CCR-08-1084","article-title":"The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma","volume":"15","author":"Chung","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-020-00936-9","article-title":"Crosstalks between inflammasome and autophagy in cancer","volume":"13","author":"Chung","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of mTOR disrupts autophagic flux in podocytes","volume":"23","author":"Cin\u00e0","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3390\/ijms19082453","article-title":"Role of mTOR signaling in tumor microenvironment: an overview","volume":"19","author":"Conciatori","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/cancers14071800","article-title":"Advanced bile duct cancers: a focused review on current and emerging systemic treatments","volume":"14","author":"Cowzer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17588359241271793","DOI":"10.1177\/17588359241271793","article-title":"Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1\/ARID1A mutations: a case report with an unexpected response","volume":"16","author":"Daugan","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ph17070910","article-title":"The recent trends of systemic treatments and locoregional therapies for cholangiocarcinoma","volume":"17","author":"Esmail","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/ijc.28214","article-title":"Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma","volume":"133","author":"Ewald","year":"2013","journal-title":"Int. J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","article-title":"Dual inhibition of PI3K\/AKT\/mTOR and RAF\/MEK\/ERK signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK inhibitors","volume":"32","author":"Ewald","year":"2014","journal-title":"Invest New Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/cancers15072105","article-title":"Precision oncology targets in biliary tract cancer","volume":"15","author":"Farha","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","article-title":"Ferroptosis is an autophagic cell death process","volume":"26","author":"Gao","year":"2016","journal-title":"Cell Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijms22010030","article-title":"Pharmacological inhibition of mTORC2 reduces migration and metastasis in melanoma","volume":"22","author":"Guenzle","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-10-4058","article-title":"mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways","volume":"71","author":"Gulhati","year":"2011","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.cell.2007.03.051","article-title":"Binding of RAS to phosphoinositide 3-kinase p110\u03b1 is required for RAS-Driven tumorigenesis in mice","volume":"129","author":"Gupta","year":"2007","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","article-title":"Hepatic mTORC2 activates glycolysis and lipogenesis through AKT, glucokinase, and SREBP1c","volume":"15","author":"Hagiwara","year":"2012","journal-title":"Cell Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"116214","DOI":"10.1016\/j.taap.2022.116214","article-title":"Albendazole-induced autophagy blockade contributes to elevated apoptosis in cholangiocarcinoma cells through AMPK\/mTOR activation","volume":"454","author":"He","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.21037\/jgo-22-298","article-title":"Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K\/AKT\/mTOR signaling pathway in human cholangiocarcinoma QBC939 cells","volume":"13","author":"He","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10585-012-9526-9","article-title":"Rapamycin inhibits motility through downregulation of p-STAT3 (S727) by disrupting mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma","volume":"30","author":"Hong","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/carcin\/bgad094","article-title":"Ferroptosis-related gene glutathione peroxidase 4 promotes reprogramming of glucose metabolism via AKT\u2013mTOR axis in intrahepatic cholangiocarcinoma","volume":"45","author":"Hori","year":"2024","journal-title":"Carcinogenesis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3892\/ol.2017.7473","article-title":"Severe acute toxicity following gemcitabine administration: a report of four cases with cytidine deaminase polymorphisms evaluation","volume":"15","author":"Hryciuk","year":"2018","journal-title":"Oncol. Lett."},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41420-025-02843-9","article-title":"Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy","volume":"12","author":"Hua","year":"2026","journal-title":"Cell Death Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41419-024-06775-7","article-title":"MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR\/SREBP1 pathway based on single-cell RNA sequencing","volume":"15","author":"Huang","year":"2024","journal-title":"Cell Death Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-018-1475-x","article-title":"Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis","volume":"16","author":"Ikeno","year":"2018","journal-title":"J. Transl. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1055\/s-0034-1394144","article-title":"Cholangiocarcinoma: molecular pathways and therapeutic opportunities","volume":"34","author":"Ilyas","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"120427","DOI":"10.1016\/j.lfs.2022.120427","article-title":"Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT\/mTOR and EMT signaling pathways","volume":"296","author":"Jaidee","year":"2022","journal-title":"Life Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.bbrc.2020.06.011","article-title":"GDC-0980 (apitolisib) treatment with gemcitabine And\/Or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K\/AKT\/mTOR pathway","volume":"529","author":"Jang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrm3522","article-title":"Amino acid signalling upstream of mTOR","volume":"14","author":"Jewell","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10517-022-05550-y","article-title":"Baicalin induced apoptosis of human cholangiocarcinoma cells through activating the AMPK\/mTORC1\/p70S6K signaling pathway","volume":"173","author":"Jia","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"785979","DOI":"10.3389\/fcell.2021.785979","article-title":"Dual inhibition of mTORC1\/2 reduces migration of cholangiocarcinoma cells by regulation of matrix metalloproteinases","volume":"9","author":"Joechle","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","article-title":"Cancer chemoresistance and its mechanisms: associated molecular factors and its regulatory role","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e2200573","DOI":"10.1200\/PO.22.00573","article-title":"Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing clinical trials","volume":"7","author":"Karasic","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.humpath.2014.03.008","article-title":"Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma","volume":"45","author":"Kubo","year":"2014","journal-title":"Hum. Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"G122","DOI":"10.1152\/ajpgi.00270.2022","article-title":"TMEM16A partners with mTOR to influence pathways of cell survival, proliferation, and migration in cholangiocarcinoma","volume":"325","author":"Kulkarni","year":"2023","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.21873\/anticanres.15169","article-title":"Adenosine induces autophagy in cholangiocarcinoma cells","volume":"41","author":"Lertsuwan","year":"2021","journal-title":"Anticancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/hep.28508","article-title":"Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"33621","DOI":"10.18632\/oncotarget.16834","article-title":"MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B57","doi-asserted-by":"publisher","first-page":"dmm033050","DOI":"10.1242\/dmm.033050","article-title":"Synergistic antiproliferative effects of an mTOR inhibitor (RAD001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity","volume":"11","author":"Lin","year":"2018","journal-title":"Dis. Model Mech."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/cancers13143517","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in breast cancer","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40364-023-00473-w","article-title":"HMGA1 augments palbociclib efficacy via PI3K\/mTOR signaling in intrahepatic cholangiocarcinoma","volume":"11","author":"Li","year":"2023","journal-title":"Biomark. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00432-024-05875-3","article-title":"Targeting the PI3K\/AKT\/mTOR pathway offers a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression","volume":"150","author":"Liang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"oyaf430","DOI":"10.1093\/oncolo\/oyaf430","article-title":"Actionable genomic landscape of biliary tract cancer in the Indian population","volume":"31","author":"Limaye","year":"2026","journal-title":"Oncologist"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3892\/or.2014.3151","article-title":"Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines","volume":"31","author":"Ling","year":"2014","journal-title":"Oncol. Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3350\/cmh.2025.0889","article-title":"Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches","volume":"32","author":"Liu","year":"2026","journal-title":"Clin. Mol. Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1074\/jbc.M111.304485","article-title":"Kinome-wide selectivity profiling of ATP-Competitive Mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"19268","DOI":"10.1038\/s41598-021-98948-z","article-title":"Tanshinone IIA affects the malignant growth of cholangiocarcinoma cells by inhibiting the PI3K\/AKT\/mTOR pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.31310","article-title":"Role of the Mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"eadj7685","DOI":"10.1126\/scitranslmed.adj7685","article-title":"SRC inhibition enables formation of a growth-suppressive MAGI1\u2013PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma","volume":"16","author":"Luk","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3892\/or.2017.5913","article-title":"c-MYC promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway","volume":"38","author":"Luo","year":"2017","journal-title":"Oncol. Rep."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3892\/ol.2017.7542","article-title":"Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the AMPK\/mTOR signaling pathway","volume":"15","author":"Lyu","year":"2018","journal-title":"Oncol. Lett."},{"key":"B72","doi-asserted-by":"publisher","first-page":"104466","DOI":"10.1016\/j.yexmp.2020.104466","article-title":"Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway","volume":"115","author":"Ma","year":"2020","journal-title":"Exp. Mol. Pathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e31112","DOI":"10.1016\/j.heliyon.2024.e31112","article-title":"Dual blockage of PI3K\/mTOR and FGFR induces autophagic cell death in cholangiocarcinoma cells","volume":"10","author":"Mahaamnad","year":"2024","journal-title":"Heliyon"},{"key":"B74","doi-asserted-by":"publisher","first-page":"11386","DOI":"10.3390\/ijms241411386","article-title":"Epithelial\u2013mesenchymal transition (EMT)","volume":"24","author":"Manfioletti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.bbadis.2017.06.005","article-title":"Chemoresistance and chemosensitization in cholangiocarcinoma","volume":"1864","author":"Marin","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2011","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41419-021-04305-3","article-title":"BET protein inhibition evidently enhances sensitivity to PI3K\/mTOR dual inhibition in intrahepatic cholangiocarcinoma","volume":"12","author":"Miao","year":"2021","journal-title":"Cell Death Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/2211-5463.12195","article-title":"TSC2\/Rheb signaling mediates ERK-Dependent regulation of mTORC1 activity in C2C12 myoblasts","volume":"7","author":"Miyazaki","year":"2017","journal-title":"FEBS Open Bio"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1101\/gad.1599207","article-title":"Autophagy: process and function","volume":"21","author":"Mizushima","year":"2007","journal-title":"Genes Dev."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3892\/ol.2014.1799","article-title":"Role of mTOR inhibitor in cholangiocarcinoma cell progression","volume":"7","author":"Moolthiya","year":"2014","journal-title":"Oncol. Lett."},{"key":"B83","doi-asserted-by":"publisher","first-page":"103749","DOI":"10.1016\/j.critrevonc.2022.103749","article-title":"Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"176","author":"Mortazavi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00795-019-00230-9","article-title":"Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location","volume":"53","author":"Nakagawa","year":"2020","journal-title":"Med. Mol. Morphol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2008.11.044","article-title":"Bidirectional transport of amino acids regulates mTOR and autophagy","volume":"136","author":"Nicklin","year":"2009","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-017-0641-y","article-title":"Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4","volume":"36","author":"Nie","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14737140.2020.1807333","article-title":"Cholangiocarcinoma: investigations into pathway-targeted therapies","volume":"20","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.21873\/invivo.13248","article-title":"FGF10\/FGFR2 signaling: therapeutically targetable vulnerability in ligand-responsive cholangiocarcinoma cells","volume":"37","author":"Oeurn","year":"2023","journal-title":"Vivo"},{"key":"B90","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00428-019-02741-3","article-title":"Activation of the AKT\/Mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis","volume":"476","author":"Okumura","year":"2020","journal-title":"Virchows Arch."},{"key":"B91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fmed.2020.00113","article-title":"Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma","volume":"7","author":"Pant","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.23736\/S0022-4707.16.06471-9","article-title":"Physical performance and positional differences among young female volleyball players","volume":"57","author":"Paz","year":"2017","journal-title":"J. Sports Med. Phys. Fit."},{"key":"B95","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00535-023-02012-8","article-title":"Dual FGFR and VEGFR inhibition synergistically restrains hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma","volume":"58","author":"Peng","year":"2023","journal-title":"J. Gastroenterol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","article-title":"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway","volume":"146","author":"Peterson","year":"2011","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jtcme.2024.04.007","article-title":"Cannabidiol suppresses proliferation and induces cell death, autophagy, and senescence in human cholangiocarcinoma cells via the PI3K\/AKT\/mTOR pathway","volume":"14","author":"Pongking","year":"2024","journal-title":"J. Tradit. Complement. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.clinre.2019.06.008","article-title":"PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma","volume":"44","author":"Qian","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J. Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","article-title":"Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer","volume":"13","author":"Rizell","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.18632\/oncotarget.2092","article-title":"Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT inhibition","volume":"5","author":"Samartzis","year":"2014","journal-title":"Oncotarget"},{"key":"B105","doi-asserted-by":"publisher","first-page":"114306","DOI":"10.1016\/j.biopha.2023.114306","article-title":"Microalga chlorella sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT\/mTOR signaling pathway","volume":"160","author":"Sawasdee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.transproceed.2025.02.001","article-title":"Transplantation for peri-hilar and intrahepatic cholangiocarcinoma with mTOR immunosuppression","volume":"57","author":"Semaan","year":"2025","journal-title":"Transpl. Proc."},{"key":"B109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.gene.2019.02.044","article-title":"Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K\/AKT\/mTOR signaling pathway","volume":"698","author":"Shen","year":"2019","journal-title":"Gene"},{"key":"B110","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","article-title":"Targeting apoptosis in cancer","volume":"24","author":"Singh","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B111","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-14-0711","article-title":"MLN0128, an ATP-Competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity as potential therapy for bone and soft-tissue sarcoma","volume":"14","author":"Slotkin","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab."},{"key":"B113","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","article-title":"Combined CDK4\/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"oyaf094","DOI":"10.1093\/oncolo\/oyaf094","article-title":"MDM2 as a therapeutic target in advanced biliary tract cancers","volume":"30","author":"Spencer","year":"2025","journal-title":"Oncologist"},{"key":"B115","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11684-020-0812-7","article-title":"mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?","volume":"15","author":"Sun","year":"2021","journal-title":"Front. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s10528-025-11097-0","article-title":"GSDME deficiency suppresses ER stress-induced autophagic cell death via mTOR\/S6K1 activation in hepatobiliary carcinomas","volume":"64","author":"Sun","year":"2026","journal-title":"Biochem. Genet."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e0334147","DOI":"10.1371\/journal.pone.0334147","article-title":"Suppression of kinesin family member-18A diminishes progression and induces apoptotic cell death of gemcitabine-resistant cholangiocarcinoma cells by modulating PI3K\/AKT\/mTOR and NF-\u03baB pathways","volume":"20","author":"Tanasuka","year":"2025","journal-title":"PLoS One"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e12750","DOI":"10.7717\/peerj.12750","article-title":"Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma","volume":"10","author":"Tessiri","year":"2022","journal-title":"PeerJ"},{"key":"B119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2017.01.139","article-title":"Targeting hexokinase II as a possible therapy for cholangiocarcinoma","volume":"484","author":"Thamrongwaranggoon","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e0245871","DOI":"10.1371\/journal.pone.0245871","article-title":"CD44 modulates metabolic pathways and altered ROS-Mediated AKT signaling promoting cholangiocarcinoma progression","volume":"16","author":"Thanee","year":"2021","journal-title":"PLoS One"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br. J. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e63326","DOI":"10.7554\/eLife.63326","article-title":"The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals","volume":"10","author":"Torrence","year":"2021","journal-title":"eLife"},{"key":"B123","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions","volume":"44","author":"Voss","year":"2013","journal-title":"Hum. Pathol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lfs.2018.05.046","article-title":"Metformin enhances cisplatin-induced inhibition of cholangiocarcinoma cells via AMPK\/mTOR pathway","volume":"207","author":"Wandee","year":"2018","journal-title":"Life Sci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.lfs.2018.12.007","article-title":"Metformin sensitizes cholangiocarcinoma cells to cisplatin-induced cytotoxicity through oxidative stress-mediated mitochondrial pathway","volume":"217","author":"Wandee","year":"2019","journal-title":"Life Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00210-021-02102-5","article-title":"Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-Mediated mitochondrial cell death, AKT\/mTOR, and FAK pathways","volume":"394","author":"Wandee","year":"2021","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/cancers15153837","article-title":"Precision medicine: disease subtyping and tailored treatment","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4149\/neo_2012_018","article-title":"Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma","volume":"59","author":"Wang","year":"2012","journal-title":"Neoplasma"},{"key":"B130","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-024-03039-2","article-title":"Augmented ERO1\u03b1 upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neo.2019.10.004","article-title":"Glutamine deprivation counteracts hypoxia-induced chemoresistance","volume":"22","author":"Wappler","year":"2020","journal-title":"Neoplasia"},{"key":"B132","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1038\/cddiscovery.2015.57","article-title":"c-MYC responds to glucose deprivation in a cell-type-dependent manner","volume":"1","author":"Wu","year":"2015","journal-title":"Cell Death Discov."},{"key":"B133","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ijms20030500","article-title":"mTOR inhibitors in advanced biliary tract cancers","volume":"20","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"key":"B135","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41420-024-02140-x","article-title":"UCK2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by PI3K\/AKT\/mTOR\/autophagic axis","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov."},{"key":"B136","doi-asserted-by":"publisher","first-page":"111965","DOI":"10.1016\/j.cellsig.2025.111965","article-title":"Circ_0084927 promotes progression of intrahepatic cholangiocarcinoma by sponging miR-4725-5p to activate the PDPK1\/AKT\/mTOR signaling pathway","volume":"134","author":"Xie","year":"2025","journal-title":"Cell Signal"},{"key":"B137","doi-asserted-by":"publisher","first-page":"156690","DOI":"10.1016\/j.phymed.2025.156690","article-title":"Fufang-biejia-ruangan tablet targets both cancer-associated fibroblasts and tumor cells via HIPPO\u2013PI3K\/AKT cascades in intrahepatic cholangiocarcinoma","volume":"141","author":"Xu","year":"2025","journal-title":"Phytomedicine"},{"key":"B138","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s12094-024-03797-7","article-title":"Autophagy in cholangiocarcinoma: a comprehensive review of roles and regulatory mechanisms","volume":"27","author":"Yang","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11010-026-05531-z","article-title":"Regulation of EMT and cholangiocarcinoma metastasis by KIN17 through the mTOR signaling pathway","volume":"481","author":"Yang","year":"2026","journal-title":"Mol. Cell Biochem."},{"key":"B141","doi-asserted-by":"publisher","first-page":"10732748211051548","DOI":"10.1177\/10732748211051548","article-title":"Trends in incidence and prognostic factors of two subtypes of primary liver cancers: a surveillance, epidemiology, and end results-based population study","volume":"29","author":"Yao","year":"2022","journal-title":"Cancer Control."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e22774","DOI":"10.1016\/j.heliyon.2023.e22774","article-title":"Prediction of immune infiltration and prognosis for patients with cholangiocarcinoma based on a cuproptosis-related lncRNA signature","volume":"10","author":"Yao","year":"2023","journal-title":"Heliyon"},{"key":"B143","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3892\/or.2017.6153","article-title":"Survival pathway of cholangiocarcinoma via AKT\/mTOR signaling to escape RAF\/MEK\/ERK pathway inhibition by sorafenib","volume":"39","author":"Yokoi","year":"2018","journal-title":"Oncol. Rep."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s12276-025-01508-y","article-title":"Regulation of transcriptome plasticity by mTOR signaling pathway","volume":"57","author":"Yong","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","article-title":"Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice","volume":"67","author":"Zhang","year":"2017","journal-title":"J. Hepatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"113399","DOI":"10.1016\/j.intimp.2024.113399","article-title":"CARD9 promotes cholangiocarcinoma by regulating the IL-17A\/Hedgehog and the THEM4\/AKT\/mTOR signaling pathways","volume":"143","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/gutjnl-2025-335729","article-title":"SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL","volume":"75","author":"Zhang","year":"2025","journal-title":"Gut"},{"key":"B148","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41392-025-02493-4","article-title":"mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"85492","DOI":"10.18632\/oncotarget.13408","article-title":"Synergistic antitumor activity of salubrinal combined with rapamycin against human cholangiocarcinoma cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"B150","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1002\/jcb.26723","article-title":"Compound C induces protective autophagy in human cholangiocarcinoma cells via AKT\/mTOR-independent pathway","volume":"119","author":"Zhao","year":"2018","journal-title":"J. Cell Biochem."},{"key":"B151","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cells13090781","article-title":"Nuclear mTOR signaling orchestrates transcriptional programs underlying cellular growth and metabolism","volume":"13","author":"Zhao","year":"2024","journal-title":"Cells"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3892\/ol.2012.928","article-title":"Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review)","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol. Lett."},{"key":"B153","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","article-title":"Ferroptosis is a type of autophagy-dependent cell death","volume":"66","author":"Zhou","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"121698","DOI":"10.1016\/j.lfs.2023.121698","article-title":"Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A\/mTOR\/SREBP1 axis in cholangiocarcinoma","volume":"327","author":"Zhou","year":"2023","journal-title":"Life Sci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e174220","DOI":"10.1172\/jci.insight.174220","article-title":"CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine\u2013glycine one-carbon metabolism","volume":"9","author":"Zhu","year":"2024","journal-title":"JCI Insight"},{"key":"B156","doi-asserted-by":"publisher","first-page":"7712817","DOI":"10.1155\/mi\/7712817","article-title":"lncRNA NKILA promotes warburg effect and immune escape in intrahepatic cholangiocarcinoma by regulating the MTX1\/TOMM40 axis","volume":"2025","author":"Zhu","year":"2025","journal-title":"Mediat. Inflamm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:39:22Z","timestamp":1784090362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":156,"alternative-id":["10.3389\/fphar.2026.1882709"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1882709","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1882709"}}